Brokers Set Expectations for MEDNAX Inc’s Q1 2018 Earnings (MD)

MEDNAX Inc (NYSE:MD) – Research analysts at William Blair cut their Q1 2018 earnings estimates for shares of MEDNAX in a note issued to investors on Tuesday. William Blair analyst R. Daniels now anticipates that the company will earn $0.78 per share for the quarter, down from their prior estimate of $0.79. William Blair also issued estimates for MEDNAX’s Q3 2018 earnings at $1.06 EPS, Q4 2018 earnings at $1.09 EPS and FY2018 earnings at $3.91 EPS.

A number of other brokerages have also commented on MD. Robert W. Baird increased their price target on MEDNAX from $48.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, February 9th. Zacks Investment Research raised MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 price target for the company in a research note on Tuesday, January 23rd. Mizuho set a $49.00 price target on MEDNAX and gave the company a “hold” rating in a research note on Wednesday, January 24th. Stifel Nicolaus reissued a “hold” rating and set a $56.00 price target on shares of MEDNAX in a research note on Wednesday, January 24th. Finally, BMO Capital Markets raised their price objective on MEDNAX from $46.00 to $58.00 and gave the company a “market perform” rating in a research note on Monday, February 12th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $54.92.

MEDNAX (MD) opened at $57.62 on Thursday. MEDNAX has a one year low of $40.56 and a one year high of $72.13. The company has a market capitalization of $5,292.88, a P/E ratio of 17.97, a P/E/G ratio of 1.40 and a beta of 0.31. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.18 and a current ratio of 1.18.

MEDNAX (NYSE:MD) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.04. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. The company had revenue of $910.82 million during the quarter, compared to analyst estimates of $884.55 million. During the same period in the prior year, the company earned $1.00 earnings per share. The firm’s revenue was up 9.6% on a year-over-year basis.

In other news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total value of $154,740.00. Following the completion of the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of the stock. GHP Investment Advisors Inc. lifted its stake in shares of MEDNAX by 13.8% during the 4th quarter. GHP Investment Advisors Inc. now owns 7,735 shares of the company’s stock worth $413,000 after acquiring an additional 940 shares during the last quarter. Amalgamated Bank lifted its stake in shares of MEDNAX by 5.9% during the 4th quarter. Amalgamated Bank now owns 18,448 shares of the company’s stock worth $986,000 after acquiring an additional 1,035 shares during the last quarter. American International Group Inc. lifted its stake in shares of MEDNAX by 0.6% during the 3rd quarter. American International Group Inc. now owns 195,583 shares of the company’s stock worth $8,434,000 after acquiring an additional 1,263 shares during the last quarter. Swiss National Bank lifted its stake in shares of MEDNAX by 0.4% during the 3rd quarter. Swiss National Bank now owns 343,000 shares of the company’s stock worth $14,790,000 after acquiring an additional 1,300 shares during the last quarter. Finally, Macquarie Group Ltd. lifted its stake in shares of MEDNAX by 36.1% during the 4th quarter. Macquarie Group Ltd. now owns 4,900 shares of the company’s stock worth $262,000 after acquiring an additional 1,300 shares during the last quarter. 95.12% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://ledgergazette.com/2018/02/22/brokers-set-expectations-for-mednax-incs-q1-2018-earnings-md.html.

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply